High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma is a research paper published in Frontiers in Oncology (2020). On theSindex it has a DataRank of 0.865. It has been cited 12 times, with 11 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.385
From this paper's citation signal
Citation Network Contribution
0.481
From 10 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 11 citers.
Bristol-Myers Squibb
FWCI
0.61
Citation Percentile
0.7%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals